Background: Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women and typically presents during adolescence. The clinical and biochemical presentation is heterogeneous, but elevated serum concentrations of androgens are the most consistent biochemical abnormality and may be considered to be the hallmark of the syndrome. Many women with PCOS also have insulin resistance and hyperinsulinaemia, which may contribute to the clinical and endocrine abnormalities. The aetiology of PCOS is not clear but studies in the Rhesus monkey suggest that exposure to excess androgen during intrauterine life results in many of the features of human PCOS, including ovarian dysfunction, abnormal LH secretion and insulin resistance. Objective: To review the studies from the literature, including those of the author, regarding aetiology, presentation and management of PCOS in adolescents. Results and conclusions: We have proposed that PCOS in adolescents arises as a result of a genetically determined disorder of ovarian function that results in hyper-secretion of androgens, possibly during fetal life and also during physiological activation of the hypothalamic-pituitary-ovarian in infancy and at the onset of puberty. There is plentiful evidence for a genetic basis for PCOS (it appears to be a complex endocrine disorder resulting from the effects of a several genes), but environmental factors, notably nutrition, influence the clinical and biochemical phenotype. Obesity unmasks or amplifies symptoms, endocrine and metabolic abnormalities. The increasing incidence of childhood obesity has resulted in an alarming Increase not only in distressing symptoms but also impaired glucose tolerance and even diabetes among adolescent girls with PCOS. The search for PCOS genes in this condition, that is not only heterogeneous but also presents only in women of reproductive age, is not straightforward and has produced few convincing candidates so far. In due course, however, identification of the major susceptibility loci is likely to provide key insight into the aetiology of the syndrome and improve diagnosis and management.
Introduction
Prevalence, presenting features and diagnosis of PCOS Polycystic ovary syndrome (PCOS) is a very common endocrine disorder, of uncertain aetiology, that affects an estimated 5-10% of women of reproductive age. PCOS typically presents during adolescence and is a heterogeneous syndrome that classically is characterized by features of anovulation (amenorrhoea, oligomenorrhoea, irregular cycles) combined with symptoms of androgen excess (hirsutism, acne, alopecia). 1 The characteristic biochemical abnormalities are elevation of serum androgen concentrations (the most consistent endocrine abnormality) and luteinizing hormone (LH) concentrations, but with normal levels of follicle-stimulating hormone (FSH). Importantly, PCOS is also associated with metabolic abnormalities, central to which are insulin resistance and hyperinsulinaemia, which carry an increased risk of developing type 2 diabetes in later life. 2, 3 It has become clear however, thanks mainly to the application of ovarian ultrasonography, that the spectrum of presentation of PCOS includes women with anovulation who have no symptoms of androgen excess (although most have raised serum androgen concentrations) as well as those with hyperandrogenism but regular menses. 2, 4 This has led to a revision of the diagnostic criteria for PCOS as a result of the joint meeting between experts from the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine. These are the so-called 'Rotterdam' criteria. The diagnosis depends on the presence of two of the three following features: polycystic ovaries, anovulation and androgen excess (clinical and/or biochemical) 5 (Table 1) . Although the Rotterdam criteria have prompted some controversy, 6, 7 these have been widely adopted in clinical practice, particularly in Europe. The principal concern that has been expressed is the inclusion of women with polycystic ovaries and anovulation but with neither clinical nor biochemical evidence of androgen excess. We have argued that there is good reason to include this subgroup within the spectrum of presentation of PCOS. 6 Nevertheless, the various subgroups of PCOS that arise from application of the Rotterdam criteria appear to have varying significance with respect to metabolic abnormalities and then the long-term consequences of PCOS. [8] [9] [10] Obesity is common in PCOS but the prevalence of overweight and obesity varies from series to series, determined partly by the nature of the clinic to which the patient is first referred. Thus the proportion of overweight/obese subjects in our own reproductive endocrinology clinic (35-40%) 2,11 is rather lower than that reported in clinic in which the primary interest is metabolic medicine (typically 480%). 3 There is ample evidence that overweight/obesity amplifies the clinical severity of PCOS and increases the risk of metabolic dysfunction. Women with PCOS are relatively more insulin resistant than those without, and increasing obesity gives rise to a disproportionate prevalence of metabolic abnormalities and their consequences in PCOS. Indeed, the prevalence of impaired glucose tolerance (IGT) in obese young women with PCOS has been estimated to be as high as 30-40%, with an additional 5-10% having frank diabetes. 12, 13 The current 'epidemic' of obesity therefore has very serious implications for the long-term health of women with PCOS. Particularly worrying is the rising tide of childhood obesity that has resulted in an increase in the prevalence and severity of symptoms of PCOS in adolescent girls (see below), although it is unlikely that the prevalence of polycystic ovaries is increasing. In other words, obesity may mean that a young woman with polycystic ovary who would otherwise have been asymptomatic (or have had mild symptoms) now suffers from symptoms of androgen excess and anovulation.
Developmental origin of PCOS and its evolution during childhood The presentation of PCOS in adolescence suggests that there is an underlying predisposition to the typical ovarian (and perhaps metabolic) abnormalities that has its origins well before the onset of puberty. We have proposed that PCOS is a genetically determined ovarian disorder characterized by excessive androgen production and that the heterogeneity of PCOS can be explained by the interaction of this disorder with environmental factors, notably dietary. 14, 15 The basis of this hypothesis resides in the observations of Abbott and colleagues regarding the results of prenatal exposure of excess androgen in female Rhesus monkeys. These animals, exposed to high concentrations of testosterone in utero, develop, as adults, many of the typical features of PCOS such as hypersecretion of LH, ovarian hyperandrogenism, anovulation in relation to increased body weight and insulin resistance. [16] [17] [18] This strongly suggests that the phenotype of PCOS represents the downstream effects of androgen excess and that these may arise by 'programming' of the hypothalamic-pituitary-ovarian axis by androgen in prenatal life. It is important to note that the Rhesus monkeys were given very large doses of androgen, high enough to exceed the normal barriers of high circulating concentrations of sex hormone-binding globulin (SHBG) and placental aromatase activity (which efficiently converts maternal androgen to oestrogens). It is very unlikely that maternal androgens, even in women with PCOS, are able to cross the placenta in significant amounts in human pregnancy, 19 which begs the question as to the origin of excess androgen in PCOS. The most likely answer is that the source of excess androgen is the foetal ovary although the adrenal may also play a role. Barnes and colleagues 20 noted clinical and biochemical manifestations of PCOS (including excess ovarian androgen production) in young adults with non-classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Contrary to previous dogma that suggested that the foetal ovary is steroidogenically inactive, it now seems possible that the ovary has the capacity to synthesize androgen in prenatal life. 21 However, even if the foetal ovary does not produce significant amounts of androgen, the postulate is that the ovary is genetically predisposed to hyperscrete androgen when the hypothalamic-pituitary axis is activated physiologically, either in early post-natal life or at puberty (or indeed both). The consequences of this increased exposure to androgen include abnormalities of LH secretion, 22 and insulin secretion and action, 14, 15 which manifest themselves during adolescence ( Figure 1 ). The idea that the genesis of PCOS is pre-pubertal is supported by the observations that polycystic ovarian morphology 23 and even clinical manifestations of androgen excess have been reported in pre-pubertal girls. 24 Premature adrenarche and premature pubarche have been linked to the aetiology of PCOS; both are associated with increased risk of PCOS during adolescence. 24, 25 Full expression of PCOS depends on the maturation of the hypothalamic-pituitary-ovarian axis that occurs during puberty. The increase in circulating levels of LH that are characteristic of normal puberty are exaggerated in girls with a predisposition to PCOS and this further amplifies ovarian androgen production. 24 The presentation of PCOS during adolescence may also be affected by metabolic changes that Polycystic ovary syndrome in adolescents S Franks are closely related to changes in body fat distribution. Normal puberty and adolescence are characterized by a physiological increase in insulin resistance along with an increase in serum concentrations of fasting insulin. 26 There is a reciprocal fall in sex hormone-binding globulin, driven by higher insulin levels and this serves to amplify the effects of sex steroids. Insulin also has a direct gonadotrophic action on ovarian steroidogenesis. These events are part of the normal cadence of puberty and provide a mechanism by which nutritional status can influence reproductive development. In girls with polycystic ovaries, the physiological hyperinsulinaemia of puberty may affect the genesis of both ovarian hyperandrogenaemia and anovulation. Insulin has been shown to amplify the steroidogenic response of both theca cells 27, 28 and granulosa cells 29, 30 to LH in the human ovary. Higher than normal insulin levels, whether due to a genetic predisposition or excessive weight gain (or both), would be expected to exaggerate these potentially adverse effects. 31 It may seem paradoxical that insulin appears to contribute to abnormal ovarian follicular function in PCOSFa state of peripheral insulin resistanceFbut recent data suggest that insulin resistance in the ovary is signalling pathway specific. Glucose uptake and metabolism by granulosa-lutein cells have been shown to be impaired [32] [33] [34] but the steroidogenic response is maintained. 34 Interaction of genes and environment in aetiology of PCOS Genetic factors. There is now compelling evidence that genetic factors are important in the aetiology of PCOS. [35] [36] [37] [38] There is familial clustering of cases 35, 36 and, crucially, a greater concordance of symptoms of PCOS in identical twins compared to non-identical twins. 38 There is also evidence for heritability of endocrine and metabolic features of PCOS. 36, 39 The mode of inheritance remains unclear; 35, 37, 40 an autosomal dominant disorder has been proposed, suggesting a single gene effect 41, 42 but the more likely proposition is that PCOS is a complex endocrine disorder involving more than one, and probably several, genes. 35, 43, 44 The search for candidate genes in PCOS has so far yielded few positive results. It is not too difficult to identify biochemical pathways that may be disrupted in PCOS. There is evidence for an intrinsic disorder of ovarian folliculogenesis, [45] [46] [47] constitutive hypersecretion of androgens by theca cells 48, 49 and disordered secretion and action of insulin 50 ( Figure 1 ).
There are, however, obvious problems in searching for candidate genes in PCOS: the heterogeneous nature of the syndrome has given rise disagreement about definition and diagnostic criteria; in addition expression of features of PCOS occurs predominantly in women of reproductive age and there is no clear male phenotypeFboth of which make family-based studies difficult. 35, 37 Many genes have been investigated as possible susceptibility loci but if PCOS is indeed a complex genetic disorder, the effect of any one gene may be small. This fact, together with the problem of ethnic heterogeneity of many populations, means that conclusive case-control (or family-based) studies require large numbers of cases and controls (at least 300 per group), homogenous populations and, very importantly, replication in other, independent populations. 37, 44, [51] [52] [53] To date more than 50 genes have been studied but few of the published studies (including some of our own initial studies) have satisfied the rigorous criteria of appropriate population selection and size, correction for comparison of multiple markers within any one population and replication in independent populations. The studies from our own laboratory provide a cautionary tale in the saga of the quest for candidate genes. On the basis of the evidence for a primary abnormality in theca cells steroidogenesis, 48, 49 we investigated a polymorphism (a pentanucleotide repeat sequence) in the promoter of CYP11A (coding for P450 cholesterol sidechain cleavage, the rate-limiting enzyme at the origin of the steroidogenic pathway) in a relatively small case-control series and a family-based study. We found evidence for linkage and association with PCOS and testosterone levels at the CYP11A locus. 54 The preliminary findings of a subsequent study by Urbanek and colleagues 55 were consistent with our results. When, however, we repeated the analysis in two large case-control populations, we could no longer find evidence of association of the polymorphism with PCOS or serum testosterone. 56 The most promising candidate gene to emerge so far is a locus on chromosome 19p13.2 (D19S884), which is close to, but not in linkage disequilbrium with, the insulin receptor gene. 57, 58 The candidate locus maps to an intron of the fibrillin 3 gene, 44 the function of which remains uncertain. 15 We suggest that the ovary is genetically predisposed to hypersecrete androgens, perhaps as early as intrauterine life but certainly during the activation of the hypothalamic-pituitary-ovarian axis that occurs transiently in infancy and in a sustained manner at puberty. Higher than normal circulating levels of testosterone 'programme' the hypothalamicpituitary unit to produce high tonic levels of luteinizing hormone (LH), and also amplify the physiological insulin resistance of puberty. Higher than normal concentrations of LH and insulin further enhance ovarian androgen production and may contribute to the mechanism of anovulation.
Polycystic ovary syndrome in adolescents S Franks formation in the ovary, 59 this presents an intriguing link to the proposed primary ovarian abnormality. Nevertheless, these interesting studies implicating the chromosome 19 locus remain to be confirmed in other large populations from independent groups. The candidate gene approach remains valid but the rate of positive 'hits' has so far proved very low. Genome-wide association studies, of the kind that has yielded positive results in another complex endocrine traitFtype 2 diabetes 60 Fmay well be the most informative approach given the now-available catalogue of genetic variation and the feasibility of high-volume phenotyping. 44 That approach will, however, require thousands of case and controls in homogeneous populations.
Intrauterine environment. For the reasons outlined above, it seems unlikely that exposure to excess maternal androgens during foetal life can directly influence the development of PCOS in the child. It remains possible, however, that maternal metabolic abnormalities during pregnancy have an effect, although there are no direct data to support this hypothesis. 61 Notably however, intrauterine growth retardation at low birth weight has been linked to an increased risk of PCOS in adolescents and adults. 25, 62 On the other hand, a survey of a large population in the north of Finland concluded that there was no association between birth weight and symptoms of PCOS in adolescents and adults. 63 For the time being then, it is important to keep an open mind about the possible non-genetic, intrauterine factors that could impact on development of PCOS.
Diet, obesity and PCOS. There is little doubt that dietary factors interact with the putative genetic influences to affect the phenotype of PCOS. Insulin resistance is a common, but by no means invariable, feature of PCOS and although it is our contention that, in most cases of PCOS, there is an underlying, primary ovarian abnormality, there is clearly an important interaction of insulin resistance/hyperinsulinaemia with the ovarian disorder. 14 The clinical and biochemical abnormalities are amplified by overweight and obesity. 2, 3 In a series of nearly 300 women with PCOS presenting to a single reproductive endocrine clinic, we found that the prevalence of hirsutism and of ovulatory dysfunction was significantly greater in overweight and obese women than in lean subjects. 64 We have recently repeated this analysis, with similar results in a larger population (n ¼ 650) of women with PCOS ( Figure 2 ). Increasing body weight is, not surprisingly, related to worsening metabolic indices. Insulin sensitivity is negatively correlated with body mass index (BMI) and fasting and glucose-stimulated plasma insulin concentrations positively associated with BMI. 50, 65 Hyperandrogenism is also exaggerated in overweight women with PCOS. Hyperinsulinaemia suppresses production of SHBG by the liver, 66 leading to higher concentrations of free testosterone, but total testosterone is also positively correlated with BMI, 67, 68 probably reflecting the effect of insulin on theca cell androgen production. Hyperinsulinaemia has also been implicated in the mechanism of anovulation. 69 As mentioned above, insulin is able to amplify the effect of LH not only on androgen production by theca but also on granulosa cell steroidogenesis. This phenomenon is associated with premature terminal differentiation of granulosa cells 70 and arrest of antral follicles. Calorie restriction (and lifestyle modification) in obese women with PCOS results in improvement in metabolic indices and in fertility with as little as a 5% reduction in body weight.
71-75
The increasing prevalence of overweight and obesity in children has given rise to numerous concerns about shortand longer-term effects. It is even more problematical for girls with a predisposition to PCOS. 24 Although there are, at the time of writing, no formal studies to chart the increasing prevalence of PCOS in adolescents, more and more clinics are dealing with obese teenagers with troublesome symptoms of PCOS. Hirsutism, persistent acne and menstrual disturbances are very distressing symptoms for adults and have even more impact in adolescent girls. Overweight and obese girls with PCOS have at least a threefold increase in risk of developing type 2 diabetes in later life and, alarmingly, IGT, and even overt diabetes, have been reported in teenagers with PCOS. 76 Another alarming, but not altogether unexpected, finding from the northern Finland cohort study, was that girls who were obese at the age of 14 were very likely to be obese at age 31; those who were obese at age 14 had a greater chance of developing symptoms of PCOS in at age 31. The highest free androgen index was found in adults who were obese at the age of 14. Polycystic ovary syndrome in adolescents S Franks and to attempt to reduce the chances of long-term complicationsFnotably type 2 diabetes. Investigation of PCOS requires only a few simple tests. The diagnosis is mainly made on the basis of clinical presentation but in girls presenting with oligo-or amenorrhoea, clinical diagnosis should be supplemented by measurements of FSH, LH and (in amenorrhoeic girls) prolactin and oestradiol. Testosterone measurements should be taken in girls with symptoms of androgen excess, mainly as a screening test to exclude other, more serious causes of androgen excess. Ultrasound examination of the ovaries (by transabdominal rather than transvaginal scanning) is helpful but arguably not mandatory in adolescents with hyperandrogenism and menstrual disturbances (they thereby fulfil the Rotterdam criteria for diagnosis of PCOS). 5 It is advisable to perform a 75 g oral glucose tolerance test routinely in girls with a BMI430 kg m
À2
. Treatment of symptoms of anovulation is mainly restricted to control of menstrual frequency in adolescent girls. Treatment of infertility is rarely an issue in this age group, although many girls wish to discuss the implication of the diagnosis for future fertility. The mainstay of management of menstrual irregularity, oligomenorrhoea or amenorrhoea is treatment with cyclical progestagens or a combined oral contraceptive (often the best option, even in adolescents). Because of the risk of endometrial hyperplasia if left untreated, such treatment is advisable even in girls with amenorrhoea (or oligomenorrhoea) who would prefer not take medication. In overweight or obese girls, it is important to offer practical advice about diet and exercise both for improvement of menstrual symptoms and for long-term management (see below).
Symptoms of androgen excess cause huge distress in adolescents and hirsutism should be treated by a combination of cosmetic management (authoritative advice about methods of hair removal is important) and, if necessary, antiandrogen therapy. 77 The most commonly used is cyproterone acetate (usually in combination with ethinyl oestradiol, as in co-cyprindiolFethinyloestradiol (35 mg) þ cyproterone actetate (2 mg)Fprescribed as Dianette in the UK). Spironolactone may also be effective and although it is not our practice to use the 'pure' antiandrogen, flutamide, there are reports of its efficacy in adolescents with PCOS. 78 There are concerns about potential hepatotoxicity with flutamide treatment but there is little evidence for liver damage with chronic low-dose use. 79 Acne will often respond to antibiotics and topical preparations but some girls with more severe acne will need treatment with anti-androgens or, under the careful supervision of the dermatologist, retinoic acid derivatives. Prevention of long-term complications of PCOS probably presents the most challenging problem. There is no doubt that diet and lifestyle changes, if rigorously applied, are effective in reducing the risk of diabetes in at-risk adults 80 but conventional weight management programmes are notoriously unsuccessful in children. 81 Metformin is also effective in reducing the incidence of diabetes in those at high risk 80 and has been used with some success in management of symptoms of PCOS in adolescents. [82] [83] [84] However there is a lack of large, randomized controlled trials to assess efficacy of symptom control in adolescents and no prospective study, even in adults, to examine the long-term effects of metformin in prevention or reduction of metabolic complications of PCOS. Recently, an impressively large and well-conducted trial of metformin as an adjunct to clomiphene treatment for induction of ovulation has shown no benefit of metformin. Although this is not immediately relevant to management of adolescents (who are unlikely to be seeking fertility treatment), it does emphasize the importance of well-conducted, large RCTs in evaluating the efficacy and safety of metformin. Although much has been learned in recent years about PCOS, there are many challenges that face us in the future. There is hope that a combination of genetic studies, and those aimed at unravelling the complexities of aberrant ovarian follicular development, will provide a better understanding of the aetiology of PCOS. Knowing more about the underlying cause(s) of the syndrome offers the prospect of new diagnostic tests and of more specific treatment strategies. But whatever is the underlying genetic basis for PCOS, it is clear that environmental factors have an essential part to play. In particular, we need to find more effective ways of preventing and controlling obesity. This is very important in women with PCOS and the fact that the syndrome often presents in adolescence offers an opportunity to intervene early enough to prevent or limit the impact of cutaneous and reproductive symptoms, and the longer-term effects of metabolic disturbance.
